Efficacy > 5L+ KarMMa Results
Proven CAR T Cell Therapy Power in the Patients You’re Likely to See1
Rapid, deep, and durable responses with ABECMA®1-3*
ORR at primary analysis (median follow-up of 13.2 months, range: 0.2-21.0): 72% ORR (95% CI, 62-81) (n=72)†
300–460 × 106 CAR-positive T cells (N=100)
ORR‡
(sCR + VGPR + PR)
72%
(95% CI, 63.2–80.8)
(n=72)
≥ VGPR: 54%
(sCR + VGPR)
(95% CI, 44.2–63.8) (n=54)
sCR§: 29%
(95% CI, 20.1–37.9) (n=29)
Deep responses were achieved in MRD-evaluable patients with ≥VGPR2
93%
MRD NEGATIVITY
in MRD-evaluable patients‖
(n=39)
- In KarMMa, 54 patients had ≥VGPR
- Of those patients, 42 were evaluable for MRD
- 93% of evaluable ≥VGPR patients were MRD negative (39/42 patients)
A majority of patients responded to ABECMA, with more than half achieving ≥VGPR
- mTTR: 1 month (range: 0.5-2.9 months; n=72)
- mDOR‡: 11.3 months (95% CI, 10.3-15.3; n=72)
- mDOR with ≥CR: 21.6 months (95% CI, 13.5-NE; n=29)
*Efficacy data based on long-term follow-up analysis (median time from ABECMA infusion to data cutoff 27.3 months [range: 24.1 to 33.1]; N=100). Data were generally consistent with the primary analysis.
†Primary analysis data: sCR 28% (95% CI, 19-38), VGPR 25% (95% CI, 17-35), PR 19% (95% CI, 12-28).
‡Response is defined as achieving ≥PR. Of the 100 patients in the efficacy-evaluable population, 25 (25%) achieved a VGPR (95% CI, 16.5-33.5) and 18 (18%) achieved a PR (95%, 10.5-25.5).4
§All complete responses were sCRs.
‖Based on a threshold of 10-5 using a ClonoSEQ® next-generation sequencing assay (NGS). MRD negativity was defined as the proportion of patients with ≥VGPR who are MRD negative at any time point within 3 months prior to achieving ≥VGPR until the time of progression or death.
CAR=chimeric antigen receptor; CI=confidence interval; mDOR=median duration of response; MRD=minimal residual disease; NE=not estimable; ORR=overall response rate; PR=partial response; sCR=stringent complete response; TTNT=time to next treatment; TTR=time to response; VGPR=very good partial response.
References:
1. ABECMA [package insert]. Summit, NJ: Bristol-Myers Squibb Company; 2025. 2. Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. [Protocol BB2121-MM-001]. N Engl J Med. 2021;384(8):1-1012. 3. Data on file. BMS-REF-IDC-0002. Princeton, NJ: Bristol-Myers Squibb Company; 2021.